Michiko Kajiwara

Tokyo, JP 
Tokyo, JP 

Overview

Michiko Kajiwara practices practicing medicine in Tokyo, Japan.

Her clinical expertise encompasses Severe Combined Immunodeficiency (SCID), Graft Versus Host Disease (GvHD), Primary Immunodeficiency (PID), Purpura, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Tokyo, Japan
Other Locations
Bunkyo, Japan
Yushima, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Biological
Study Drug: TAK-755
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: BAX930
Study Phase: Phase 3
View 1 Less Clinical Trial

41 Total Publications

Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.
Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.
Journal: British journal of haematology
Published: October 09, 2025

Frequently Asked Questions about Michiko Kajiwara

Is Michiko Kajiwara a top-rated expert for Severe Combined Immunodeficiency (SCID)?

MediFind is an objective health platform that identifies experts based on real-world data. Michiko Kajiwara is classified as an Experienced expert for Severe Combined Immunodeficiency (SCID), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michiko Kajiwara participate in research or clinical trials?

Yes. Michiko Kajiwara has published 41 articles and abstracts on conditions like Severe Combined Immunodeficiency (SCID). You can view a list of Michiko Kajiwara's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kajiwara's expertise for a condition
ConditionClose
        View All 16 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile